The INTESTINE study: INtended TEmporary STomas In crohN’s diseasE. Protocol for an international multicentre study

Valerio Celentano1,2 · Claire Perrott1 · Patricia Tejedor3 · Giacomo Calini4 · Matteo Rottoli5,6 · Christos Kontovounios1,2 · Paris Tekkis1,2

Received: 25 June 2022 / Accepted: 27 July 2022 / Published online: 12 August 2022 © The Author(s) 2022

Abstract
Surgery for ileocolonic Crohn’s disease can result in temporary or permanent stoma formation which can be associated with morbidity as parastomal and incisional hernias, readmissions due to obstruction or high stoma output, and have a negative impact on quality of life. We propose an international retrospective trainee-led study of the outcomes of temporary stomas in patients with Crohn’s disease. We aim to evaluate both the short-term (6 month) and mid-term (18 month) outcomes of temporary stomas in patients with Crohn’s Disease. Retrospective, multicentre, observational study including all patients who underwent elective or emergency surgery for ileal, colonic and ileocolonic Crohn’s disease during a 4-year study period. Primary outcome is the proportion of patients who still have an ileostomy or colostomy 18 months after the initial surgery. Secondary outcomes: complications related to stoma formation and stoma reversal surgery; time interval between stoma formation and stoma reversal; risk factors for stoma formation and non-reversal of the stoma. We present the study protocol for a trainee-led, multicentre, observational study. Previous research has demonstrated significant heterogeneity surrounding the formation and the timing of reversal surgery in patients having a temporary ileostomy following colorectal cancer surgery, highlighting the need to address these same questions in Crohn’s disease, which is the aim of our research.

Keywords Crohn’s disease · Inflammatory bowel disease · Ileostomy · Colostomy

Background
Europe has one of the highest prevalence of inflammatory bowel disease (IBD) across the world [1]. In the UK 115,000 patients are affected by Crohn’s disease (CD) [2] and up to 80% of these patients will require surgical intervention at some point in their lives, despite medical treatment [3]. Indications for surgery include perianal disease, enteric fistulae, perforation, obstruction, strictures and medically refractory disease. Surgical resection can result in temporary or permanent stoma formation which can be associated with morbidity due to parastomal and incisional hernias, prolapse and have a negative impact on quality of life. The formation of stomas can cause prolonged and repeated hospital admissions due to high output or bowel obstruction, and other stoma-related complications.

Patients with ileocolonic CD often undergo multiple operations throughout their lives and so are exposed to these risks at each procedure. Key performance indicators (KPIs) can be used as a quality measurement to monitor standards of care across a variety of healthcare settings, and KPIs for the surgical management of Inflammatory Bowel Disease have been proposed by a Delphi Consensus study [4] including not only postoperative complications and rate of re-interventions and readmissions but also the proportion of patients who had a defunctioning stoma and if this was reversed in a timely fashion.
Currently, no study has investigated what happens to these temporary stomas in CD and whether planned reversals happen and if not, what are the reasons.

**Aims**

We propose an international retrospective trainee-led snapshot study of the outcomes of temporary stomas in patients with Crohn’s disease. We aim to evaluate both the short-term (6 month) and mid-term (18 month) outcomes of intended temporary stomas in patients with Crohn’s Disease.

**Methods**

**Study design**

International, retrospective, multicentre, observational study.

**Study objectives**

(a) To determine the proportion of temporary stomas reversed at 6- and 18-months post formation in patients with Crohn’s disease.
(b) To determine the time interval between stoma formation and stoma reversal.
(c) To determine risk factors for the formation of temporary stoma and risk factors for delayed or no reversal.
(d) To establish the morbidity related to the presence of a stoma in patients with Crohn’s disease
(e) To inform the consenting process for patients undergoing Crohn’s Disease surgery, by acknowledging risk factors for delayed or no reversal.

**Study setting**

International retrospective multicentre study was designed according to the SPIRIT guidelines [5]. Participating centres must hold a regular IBD MDT and have dedicated IBD colorectal surgeons and gastroenterologists. Participating Centres must provide a local lead and a local trainee lead. Study steering group includes patients’ representatives, surgical trainees, colorectal surgeons with expertise in CD surgery, methodological leads with expertise in leading and developing multicentre studies.

**Study participants**

Patients who have had a stoma formation for Crohn’s Disease.

**Inclusion criteria**

The participant must meet the following criteria to be considered eligible for inclusion in the study:

– Aged 18 years or over
– Underwent an intended temporary stoma formation for Crohn’s disease
– Between January 2017–December 2020, the 4-year study recruitment period.
– Follow-up of 18 months for each patient
– Either elective or urgent/emergency surgery
– The procedures included are:
  o ileocolonic resection (right hemicolectomy, extended right hemicolectomy, ileocaecal resection, redo ileocolic resection),
  o segmental colonic resections including subtotal colectomy, left hemicolectomy, transverse colectomy, anterior resection, Hartmann’s procedure,
  o small bowel resection, strictureplasty as a sole procedure,
  o formation of ileostomy or colostomy as a sole procedure for the treatment of complex ileocolic disease or perianal disease.

**Exclusion criteria**

– Excluded procedures will be panproctocolectomy and proctectomy.

**Primary outcome**

The proportion of patients who still have an ileostomy or colostomy 18 months after the initial surgery.

**Secondary outcomes**

– Complications related to stoma formation and stoma reversal surgery.
– Time interval between stoma formation and stoma reversal
– Risk factors for stoma formation and non-reversal of the stoma.

**Subgroup analysis**

The cohort of patients having a stoma in the context of colonic CD or perianal CD will be separately evaluated for the primary and secondary outcomes.
Accessory evaluation

The impact of Covid on the reversal rate of stomas. To compare the rate and timing of stoma reversal pre and post the Covid pandemic, if there is overlap in the data.

Sample size

We aim to evaluate what happens to patients who had a stoma formed during their surgery for CD and therefore there is no need to limit the sample size to a specific number of patients being this is a snapshot study [6]. For the statistical analysis in the group of patients having ileocaecal or redo ileocolic resection, the minimum sample size was calculated considering an 11% incidence of new stoma formation in patients undergoing surgery for ileocolonic CD, according to previously published literature [7]. With a confidence level of 95% and error margin of 5%, 151 patients were required.

Study procedures

First, the study was registered at Chelsea and Westminster Hospital. Subsequently, the study will be disseminated to IBD centres worldwide, to involve IBD consultant surgeons to act as lead consultants and trainee leads for each participating centre. We will use virtual meetings to communicate with centres and use email to circulate information on the methodology for data collection. The recruitment of new centres will continue during the data collection period. A national/region all study lead will be identified for each participating country to act as a bridge between each participating centre and the study steering group.

Ethical considerations

All data collected will measure current practice, with no changes made to normal treatment. As such, this study should be registered as an audit of current practice at each participating centre. It is the responsibility of the local team at each site to ensure that local audit approval (or equivalent) is completed for their centre. Participating centres will be asked to confirm that they have gained formal approval at their site. When required, ethical approval will be sought by the individual participating centres according to local policies.

Data collection

We will allocate 12 weeks for data collection. Initially, each centre will review clinical records to identify patients who underwent Crohn’s disease surgery which involved the formation of an ileostomy or colostomy. Data will be collected on these patients including:

- **Demographic data**: Age, gender
- **Disease-specific information**: Crohn’s phenotype and Montreal classification [8], history of previous surgery, preoperative medical treatments, body mass index and preoperative weight loss. Harvey–Bradshaw disease activity score [9].
- **Surgery specific**: indication for surgery, surgery scheduling (elective, emergency) operation performed, surgical approach (laparoscopic, open, robotic), indication for the stoma including, the type of stoma created (ileostomy/colostomy) and if any plans for stoma reversal are stated.
- **Surgical outcomes**: the length of hospital stay, 30-day morbidity (according to Dindo-Clavien classification) [10], for both the index surgical procedure when the stoma was fashioned and for the stoma reversal surgery (if performed), long-term data on whether stoma had been reversed at 6 and 18 months and if any complications relating to the stoma occurred in the meantime.
- **Patient Reported Outcome Measures (PROMs)**: Data on PROMs will be included if collected.

Sites will be expected to identify eligible patients from the established database, operating theatre registries, IBD MDT registries, and clinical coding searches.

Statistical analysis

Categorical variables are presented as frequency and percentages, and compared using the chi-square test or Fisher’s exact test, as appropriate. Continuous variables are presented as mean (± standard deviation) or median (range) according to their distribution and compared with the use of Student’s t test or the Mann–Whitney U test in case of normal or skewed distribution, respectively. To identify variables associated with binary outcomes, univariable and multivariable logistic regression analyses will be performed. Variables having a p value equal to 0.10 or less at the univariate analysis will be included in the multiple regression model. The Odds ratio (ORs) with a 95% confidence interval (CI) was estimated as a measure of association. Statistical analysis will be performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY, USA).
Data storage

Data will be collected and stored on the Research Electronic Data Capture (REDCap) of the University of Bologna. No patient identifiable data (name, date of birth, address, etc.) will be recorded on REDCap. Registered local investigators will have individual password-protected access to their unit’s data entered onto REDCap. During the running of the audit, only local data will be visible to investigators; other sites’ data will not be accessible.

Timetable

– Recruitment and dissemination of study protocol: Month 1 to month 4.
– Data collection: Month 5 to month 8.
– Analysis: Month 9 to Month 10
– Writing up reports/publications/dissemination: Month 11 onwards.

Dissemination plan

The findings will be disseminated using multiple routes, including:

– Relevant webpages, social media, events of Crohn’s disease, IBD and colorectal conditions charities.
– Locally at our annual research and Innovation conference.
– Presentation at National and International conferences.
– Published in peer-reviewed academic journals.
– Professional media and accessible formats presented to already established focus groups of patients.

Authorship

Collaborative authorship will be offered to local leads and trainees at each centre for submissions to peer-reviewed journals.

Discussion

The presence of a stoma can significantly affect patients’ quality of life [11, 12] and has also a risk of complications and re-interventions [13]. Stoma rates up to 35% have been described for complicated CD [14] and a penetrating phenotype of CD may explain a more common use of stomas in selected patients, because of abscesses and intra-abdominal contamination, or due to complex internal fistulae requiring more than one intestinal resection. Previous studies have reported a successful reversal rate in only 16.6% of patients having an intended temporary stoma for the treatment of perianal CD [15], demonstrating that any stoma fashioned in patients with CD must not be assumed as temporary.

Unfortunately, many key performance indicators of CD surgery such as postoperative morbidity, rate of ileostomy formation, reoperations and readmissions are not routinely recorded, with a paucity of audits on Patients Reported Outcome Measures (PROMs) [4].

Our study aims to fill this gap in the literature, and the collaborative nature of this multicentre study, will allow capturing real-world data on the current use of stomas in patients with CD and on the complications related to the stoma formation and reversal. One in five patients are readmitted with a stoma-related complication within 30 days of the creation of an ileostomy, with dehydration being the leading cause, occurring in 6% of patients [16]. The rate of stoma-related complications will likely be higher during the 18-months follow-up of our study, reflecting the high health care cost for a potentially avoidable cause, including long-term complications, which often require further surgery or contribute to mortality [11].

Previous studies in CD surgery have demonstrated significant variability across different hospitals in the volume of surgical procedures performed per year, the short-term surgical outcomes, and the adoption of minimally invasive surgery [17]. It is not surprising to highlight variations in IBD surgical practice, as similarly, the wide range of available treatments for IBD has been shown to result in significant heterogeneity amongst physicians in the use of biologics and combination therapy, confirming the need for standardised pathways for the care of IBD patients [18], and guidelines of several international societies have been released to optimize CD outcomes [19, 20].

The results of our study could contribute to the discussion on the centralisation of services for complex CD surgery [21], by obtaining real-world data on current practice in CD. We expect that our study will demonstrate divergence across different hospitals and countries in the proportion of CD patients having their temporary stomas reversed, and in the time gap between stoma formation and reversal, considering the potential higher risk of complications when this gap is longer.

We must acknowledge that not all stomas in patients with CD are intended as temporary, as for example in case of severe perianal involvement, or when there is an extensive multi-level disease in the bowel segments distal to the stoma, and the retrospective design of our study might not be able to capture these exemptions, similarly to stomas not reversed as per patients’ preference. Nevertheless, awareness of the proportion of CD patients who successfully have their stoma reversed in a timely manner could forge counselling and decision making, as for example in patients with complicated colonic diverticulitis who have a Hartmann’s procedure, which is never reversed up to 40%
of the patients [22]. Previous research has demonstrated the significant heterogeneity surrounding the formation, and more importantly, the timing of reversal surgery in patients having a temporary ileostomy following anterior resection for cancer [23], highlighting the need to address these same questions in CD surgery as well.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13304-022-01345-y.

Funding No funding has been received for the study.

Declarations

Conflict of interest The principal investigators and co-authors declare no conflict of interest.

Ethical approval The study has been approved by the appropriate institutional research ethics and we certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The original author is licenced under a Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ng S, Shi H, Hamidi N et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769–2778

2. National Institute for Health and Care Excellence. (2015). Inflammatory bowel disease Quality standard [QS81]. https://www.nice.org.uk/guidance/qs81/chapter/introduction#:~:text=In%20the%20UK%2C%20at%20least,0%20of%20active%20disease.%20 Last accessed 05/02/2021

3. Bernell O, Lapidus A, Hellers G (2000) Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg 87:1697–1701

4. Morar P, Hollingshead J, Bemelman W, Sevdalis N et al (2017) Establishing key performance indicators [KPIs] and their importance for the surgical management of inflammatory bowel disease-results from a Pan-European, Delphi Consensus Study. J Crohns Colitis 11(1):1362–1368

5. Chan A-W, Tetzlaff JM, Altmann DG, Laupacis A, Götzsche PC, Krkleza-Jerkić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 158(3):200–207

6. 2015 European Society of Coloproctology collaborating group. Risk factors for unfavourable postoperative outcome in patients with Crohn’s disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO. Colorectal Dis. 2017

7. Celentano V, O’Leary DP, Caiazzo A, Flashman KG, Sagias F, Conti J, Senapati A, Khan J (2019) Longer small bowel segments are resected in emergency surgery for ileocaecal Crohn’s disease with a higher ileostomy and complication rate. Tech Coloproctol 23(11):1085–1091. https://doi.org/10.1007/s10151-019-02104-9

8. Silverberg MS, Satsangi J, Ahmad T et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(suppl A):5–36

9. Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s disease activity. Lancet 315(8167):514

10. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213

11. Schiergens TS, Hoffmann V, Schobel TN et al (2017) Long-term quality of life of patients with permanent end ileostomy: results of a nationwide cross-sectional survey. Dis Colon Rectum 60(1):51–60

12. Knowles SR, Wilson J, Wilkinson A et al (2013) Psychological well-being and quality of life in Crohn’s disease patients with an ostomy: a preliminary investigation. J Wound Ostomy Continence Nurs 40(4):623–629

13. Scarpa M, Ruffolo C, Bassi D et al (2009) Intestinal surgery for Crohn’s disease: predictors of recovery, quality of life, and costs. J Gastrointest Surg 13(12):2128–2135

14. Goyer P, Alves A, Bretagnol F, Bouhnik Y, Valleur P, Panis Y (2009) Impact of complex Crohn’s disease on the outcome of laparoscopic ileocaecal resection: a comparative clinical study in 124 patients. Dis Colon Rectum 52:205–210

15. Singh S, Ding NS, Mathis KL, Duliak PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV Jr (2015) Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 42(7):783–792

16. Vogel I, Shinkwin M, van der Storm SL, Torkington J, Cornish J, Tanis PJ, Hompes R, Bemelman WA (2022) Overall readmissions and readmissions related to dehydration after creation of an ileostomy: a systematic review and meta-analysis. Tech Coloproctol. https://doi.org/10.1007/s10151-022-02580-6

17. SICCR Current Status of Crohn’s Disease Surgery Collaborative (2021) National variations in perioperative assessment and surgical management of Crohn’s disease: a multicentre study. Colorectal Dis 23(1):94–104

18. Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheume RL, Sandler RS (2015) Variations in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol 13(6):1197–1200. https://doi.org/10.1016/j.cgh.2014.11.020

19. Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burton J, Collins P, Doherty G, El-Hussana A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Goemillon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustens E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O (2020) ECCO
guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis 14(2):155–168. [https://doi.org/10.1093/ecco-jcc/jjz187]

20. Pellino G, Keller DS, Sampietro GM, Annese V, Carvello M, Celentano V, Coco C, Colombo F, Cracco N, Di Candido F, Franceschi M, Laureti S, Mattioli G, Pio L, Sciaudone G, Sica G, Villanacci V, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; the Italian Society of Colorectal Surgery (SICCR) (2020) Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. Tech Coloproctol 24(2):105–126. [https://doi.org/10.1007/s10151-019-02145-0]. Epub 2020 Jan 25. Erratum in: Tech Coloproctol. 2020 Jun 20

21. Rottoli M, Pellino G, Tanzanu M, Baldi C, Frontali A, Carvello M, Foppa C, Kontovounisios C, Tekkis P, Colombo F, Sancho-Muriel J, Frasson M, Danelli P, Celentano V, Spinelli A, Panis Y, Sampietro GM, Poggioli G (2021) Inflammatory Bowel Disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIBD-Surg). Updates Surg 73(5):1811–1818. [https://doi.org/10.1007/s13304-021-01119-y]. Epub 2021 Jun 26. Erratum in: Updates Surg. 2021 Sep 7

22. Celentano V, Giglio MC, Bucci L (2015) Laparoscopic versus open Hartmann’s reversal: a systematic review and meta-analysis. Int J Colorectal Dis 30(12):1603–1615

23. Dukes’ Club Research Collaborative (2021) Factors impacting time to ileostomy closure after anterior resection: the UK closure of ileostomy timing cohort study (CLOSE-IT). Colorectal Dis 23(5):1109–1119. [https://doi.org/10.1111/10.1111/codi.15531 (Epub 2021 Feb 18)]

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.